Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Gross Margin (2016 - 2025)

Historic Gross Margin for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to 99.86%.

  • Lineage Cell Therapeutics' Gross Margin rose 8700.0% to 99.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 97.84%, marking a year-over-year increase of 28400.0%. This contributed to the annual value of 96.48% for FY2024, which is 39900.0% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Gross Margin stood at 99.86%, which was up 8700.0% from 98.59% recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Gross Margin peaked at 99.86% during Q3 2025, and registered a low of 1.93% during Q4 2021.
  • Over the past 5 years, Lineage Cell Therapeutics' median Gross Margin value was 94.67% (recorded in 2022), while the average stood at 85.75%.
  • In the last 5 years, Lineage Cell Therapeutics' Gross Margin plummeted by -659600bps in 2021 and then surged by 927500bps in 2022.
  • Lineage Cell Therapeutics' Gross Margin (Quarter) stood at 1.93% in 2021, then surged by 4810bps to 94.67% in 2022, then decreased by -7bps to 87.74% in 2023, then increased by 8bps to 94.63% in 2024, then rose by 6bps to 99.86% in 2025.
  • Its Gross Margin stands at 99.86% for Q3 2025, versus 98.59% for Q2 2025 and 97.6% for Q1 2025.